With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...

In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest heal ...

Photo by Flickr user Ian Wilson Doctors will no longer be paid to speak on behalf of GlaxoSmithKline and its products, the British drug maker said Tuesday. In addition, the pharmaceutical company ...

GlaxoSmithKline and Vir finally score $1B supply deal for COVID antibody—6 months after FDA nod Continued emergence of omicron could spark a rush of sales for GSK-Vir's antibody therapy.

CARLISLE - GlaxoSmithKline, one of the world’s largest pharmaceutical companies, confirmed Monday that it will close a manufacturing facility in Carlisle next year. Production in Carlisle will ...

U.K.-based pharmaceutical giant GlaxoSmithKline currently sits nearly 50% off the all-time highs it set way back in 1999. Over its 300 year history , the company has been behind some of the most ...

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.

Drug maker GlaxoSmithKline said it will lay off hundreds of its U.S. workers to reduce costs and to streamline its research and drug-marketing operations by the end of 2015.